CN106822271A - It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use - Google Patents
It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use Download PDFInfo
- Publication number
- CN106822271A CN106822271A CN201710108922.8A CN201710108922A CN106822271A CN 106822271 A CN106822271 A CN 106822271A CN 201710108922 A CN201710108922 A CN 201710108922A CN 106822271 A CN106822271 A CN 106822271A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- pharmaceutical composition
- preparation
- bulk drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Pharmaceutical composition of rheumatic Bi syndrome and its production and use is treated the invention discloses a kind of.The pharmaceutical composition of present invention treatment rheumatic Bi syndrome, 20~40 parts of notopterygium root, 10~30 parts of levisticum, 40~60 parts of the root of Chinese clematis, 10~30 parts of Radix Angelicae Sinensis, 30~50 parts of wild aconite root, 10~30 parts of paniculate swallowwort, 60~80 parts of thunder godvine, 20~40 parts of the root of fangji, 40~60 parts of frankincense.Pharmaceutical composition of the present invention can effectively treat rheumatism, to rheumatoid arthritis, rheumatic arthritis, flesh rheumatism, osteoproliferation determined curative effect, in order to clinical treatment rheumatism provides a kind of new selection, application prospect is good.
Description
Technical field
Pharmaceutical composition of rheumatic Bi syndrome and its production and use is treated the present invention relates to a kind of.
Background technology
Rheumatism is a kind of common clinical, frequently-occurring disease, is due to exopathogens such as wind, cold, wet, heat while being also a kind of persistent ailment
Body is attacked in an opponent's defence, impatency channels and collaterals, QI-blood circulation is not smooth, cause muscle, muscles and bones, joint pain, numbness, joint stuffiness, or even
The scorching hot class disease of arthrocele.Rheumatism is Traditional Chinese Medical Concepts, equivalent to the chronic auto-immune systemic disease of modern medicine, such as
The connective tissue diseases such as rheumatic arthritis, rheumatoid arthritis, osteoproliferation, spondylitis, scapulohumeral periarthritis, osteoarthritis, its
Main clinical manifestation is redness and swelling of joints heat pain, and swelling deforms, and involving in one or more joints, or even articular cavity has liquid to ooze
Go out, function limitation (morning stiffness), what is had causes life-long disabilities, it is a kind of not dead cancer to be commonly called as rheumatism
Rheumatism be it is a kind of clinically, common disease and frequently-occurring disease, the pathogenic factor and pathogenesis of rheumatism are because of complexity, the cause of disease
It is indefinite, therefore treatment rheumatism, at present without effective treatment method, western medicine is not thorough, and side effect is larger, with medicine
Thing dependence, seriously compromises the organ functions such as liver, kidney.Using traditional Chinese medicine is for oral administration, washout, the method for hot compress, can be from disease
Entirety is set out, and pigtail card opinion is controlled, with some superiority.
The content of the invention
It is an object of the invention to provide a kind of pharmaceutical composition of new treatment rheumatic Bi syndrome.
A kind of pharmaceutical composition for treating disadvantage disease, it is the system being prepared from by the bulk drug comprising following weight proportion
Agent：
20~40 parts of notopterygium root, 10~30 parts of levisticum, 40~60 parts of the root of Chinese clematis, 10~30 parts of Radix Angelicae Sinensis, 30~50 parts of wild aconite root,
10~30 parts of paniculate swallowwort, 60~80 parts of thunder godvine, 20~40 parts of the root of fangji, 40~60 parts of frankincense.
Frankincense of the present invention refers to stir-baked OLIBANUM with vinegar.
Preferably, it is the preparation being prepared from by the bulk drug comprising following weight proportion：30 parts of notopterygium root, levisticum 20
Part, 50 parts of the root of Chinese clematis, 20 parts of Radix Angelicae Sinensis, 40 parts of wild aconite root, 20 parts of paniculate swallowwort, 70 parts of thunder godvine, 30 parts of the root of fangji, 50 parts of frankincense.
It is further preferred that it is the preparation being prepared from by the bulk drug of following weight proportion：30 parts of notopterygium root, levisticum 20
Part, 50 parts of the root of Chinese clematis, 20 parts of Radix Angelicae Sinensis, 40 parts of wild aconite root, 20 parts of paniculate swallowwort, 70 parts of thunder godvine, 30 parts of the root of fangji, 50 parts of frankincense.
Wherein, the composition be by the medicinal powder of bulk drug, the water of bulk drug or extractive with organic solvent be active component,
Plus the preparation that pharmaceutically conventional auxiliary material or complementary composition are prepared from.
Wherein, the preparation is oral formulations.The preparation is capsule, decoction, oral liquid, granule, powder, ball
Agent, tablet.
The preparation method of foregoing pharmaceutical composition of the present invention, step is as follows：
(1) bulk drug is weighed according to foregoing proportioning；
(2) medicinal powder, the water or extractive with organic solvent of bulk drug of material medicine are prepared, pharmaceutically conventional auxiliary material or auxiliary is added
Helping property composition, obtains final product.
Present invention also offers purposes of the foregoing pharmaceutical composition in the medicine for preparing treatment rheumatism.Wherein, the medicine
Thing is the medicine for treating rheumatoid arthritis, rheumatic arthritis, flesh rheumatism and/or osteoproliferation.
Theory of traditional Chinese medical science thinks that mainly due to deficiency of vial QI, rheumatism cold-evil take advantage of a weak point for the generation of bi Zheng, invasion and attack channels and collaterals,
Muscle, muscles and bones, joint etc., cause channels and collaterals, qi and blood to declare logical caused.Therefore, the rules for the treatment of are except the medicine for using wind-dispelling, cold dispelling, dehumidifying
Beyond the region of objective existence, also to coordinate promoting blood circulation, activate yang, qi-regulating and fill blood, the medicine of liver and kidney benefiting.We select notopterygium root, levisticum expelling wind and eliminating dampness,
Numbness relieving and pain relieving is monarch drug in a prescription, is aided with the root of Chinese clematis, the root of fangji, strengthens the expelling wind and removing dampness effect of monarch drug in a prescription, wild aconite root, thunder godvine, full worm Wen Jing
Cold dispelling, to help main ingredient to remove the cloudy heresy of cold-dampness of channels and collaterals joint depths, is altogether ministerial drug.Radix Angelicae Sinensis, frankincense, myrrh promoting blood circulation, dredging collateral stop
Pain is adjutant, and lycopodium calvatum is stimulated the circulation of the blood and cause the muscles and joints to relax and thinks and make medicine.All medicines share, play altogether expelling wind and removing dampness cold dispelling relax degrading the channel, promoting blood circulation and stopping pain it
Effect.Wind-cold damp pathogen is dispelled, and QI of channels and collaterals is unobstructed, and joint is removed certainly from profit, bi Zheng.Therefore have notable therapeutic effect to wind-cold-dampness arthralgia.
Pharmaceutical composition of the present invention can effectively treat rheumatism, to rheumatoid arthritis, rheumatic arthritis, flesh wind
Wet, osteoproliferation determined curative effect, in order to clinical treatment rheumatism provides a kind of new selection, application prospect is good.
The present invention is described in further details below by specific embodiment, but is not to limit of the invention
System, the above of the invention, according to the ordinary technical knowledge and customary means of this area, not departing from, the present invention is above-mentioned
Under the premise of basic fundamental thought, the modification of other diversified forms can also be made, is replaced or is changed.
Specific embodiment
The preparation of the pharmaceutical composition of the present invention of embodiment 1
【Prescription】Notopterygium root 30g levisticum 20g root of Chinese clematis 50g Radix Angelicae Sinensis 20g wild aconite root 40g paniculate swallowwort 20g thunder godvines 70g
Root of fangji 30g frankincenses 50g
【Preparation method】The taste of the above nine, is mixed, and crushes, and dries, and crosses No. five sieves, loads No. 0 Capsules, and bottling is obtained final product.
【Proterties】This product is capsule, and content is light brown powder, and gas is micro-, mildly bitter flavor.
【Specification】0.5 gram/, 100 × 0.5 grams// bottle.
【Function with cure mainly】Expelling wind and removing dampness, it is warming channel and expelling cold, dredge through dredging collateral, promoting blood circulation and stopping pain.It is mainly used in treating arthralgia pain due to rheumatism
(rheumatoid arthritis, rheumatic arthritis), flesh rheumatism, osteoproliferation etc..
The preparation of the pharmaceutical composition of the present invention of embodiment 2
【Prescription】Notopterygium root 20g levisticum 10g root of Chinese clematis 40g Radix Angelicae Sinensis 10g wild aconite root 30g paniculate swallowwort 10g thunder godvines 60g
Root of fangji 20g frankincenses 40g
【Preparation method】The taste of the above nine, is mixed, and crushes, and dries, and crosses No. five sieves, loads No. 0 Capsules, and bottling is obtained final product.
【Proterties】This product is capsule, and content is light brown powder, and gas is micro-, mildly bitter flavor.
【Specification】0.5 gram/, 100 × 0.5 grams// bottle.
【Function with cure mainly】Expelling wind and removing dampness, it is warming channel and expelling cold, dredge through dredging collateral, promoting blood circulation and stopping pain.It is mainly used in treating arthralgia pain due to rheumatism
(rheumatoid arthritis, rheumatic arthritis), flesh rheumatism, osteoproliferation etc..
The preparation of the pharmaceutical composition of the present invention of embodiment 3
【Prescription】Notopterygium root 40g levisticum 30g root of Chinese clematis 60g Radix Angelicae Sinensis 30g wild aconite root 50g paniculate swallowwort 30g thunder godvines 80g
Root of fangji 40g frankincenses 60g
【Preparation method】The taste of the above nine, is mixed, and crushes, and dries, and crosses No. five sieves, loads No. 0 Capsules, and bottling is obtained final product.
【Proterties】This product is capsule, and content is light brown powder, and gas is micro-, mildly bitter flavor.
【Specification】0.5 gram/, 100 × 0.5 grams// bottle.
【Function with cure mainly】Expelling wind and removing dampness, it is warming channel and expelling cold, dredge through dredging collateral, promoting blood circulation and stopping pain.It is mainly used in treating arthralgia pain due to rheumatism
(rheumatoid arthritis, rheumatic arthritis), flesh rheumatism, osteoproliferation etc..
Hereinafter beneficial effects of the present invention are proved with the mode of experimental example：
The drug therapy rheumatoid arthritis of the present invention of experimental example 1
1st, clinical data
1.1 diagnostic criteria
1st, morning get up anchylosis, continue at least 1 hour.
2nd, there is the soft tissue swelling (arthritis) of the joint part of 3 or more than 3.
3rd, metacarpophalangeal joints, PIP or type joint swelling were more than 6 weeks or 12 weeks.
4th, symmetrical swelling (arthritis), both the identical joint in body both sides was while or first sequela.
5th, subcutaneous rheumatoid nodules.
6th, X-ray film display hand and (or) wrist joint cartilage surface are in that rotten to the corn sample and (or) periarticular osteoporosis change.
7th, rheumatoid factor positive.
Remarks：The above 1-4 has to last at least 6 weeks or 12 weeks occur.Possess 4 or more than 4 persons, it is diagnosable to be
Rheumatoid arthritis.
1.2 inclusive criterias
The case for meeting 1.1 section diagnostic criteria is included, totally 20.
2nd, treatment method
Experimental group：Give the medicine of the embodiment of the present invention 1.
Usage and dosage：Orally, one time 5~6,3 times a day.2 small space-times take after meal, and plain boiled water send down.
3rd, observation of curative effect
3.1 criterions of therapeutical effect
Situation about alleviating according to patient clinical symptom is divided into effective：Range of motion recovers substantially, and pain is relieved；Have
Effect：Range of motion takes a turn for the better before relatively treating, pain relief；It is invalid：Range of motion and pain are compared with pre-treatment without improvement.
3.2 treatment results
As shown in table 1：
| Group | It is effective | Effectively | It is invalid | Total effective rate |
| Experimental group (50 people) | 48 | 2 | 0 | 100% (50/50) |
Experimental result illustrates that medicine of the present invention can effectively treat rheumatoid arthritis.
The drug therapy osteoproliferation of the present invention of experimental example 2
1st, clinical data
1.1 diagnostic criteria
1. pain in the back, morning lifting, mitigate after activity；Multi-activity or pain in the back is aggravated again after bearing a heavy burden, with it is sour it is swollen, uncomfortable based on；
Section of two or three hyperplasia of lumbar vertebrae
Section of two or three hyperplasia of lumbar vertebrae
2. many without clear and definite tender point；
3. waist limitation of activity；
4. waist has tunked comfort sense；
5. not with neurothlipsis sign；
6.X pieces display centrum has osteophytosis, stenosis of disc space.
Meet above-mentioned 6 and be diagnosed as lumbar vertebrae hyperosteogeny.
1.2 inclusive criterias
The case for meeting 1.1 section diagnostic criteria is included.
2nd, treatment method
Experimental group：Give the medicine of the embodiment of the present invention 1.
Usage and dosage：Orally, one time 5~6,3 times a day.2 small space-times take after meal, and plain boiled water send down.
3rd, observation of curative effect
3.1 criterions of therapeutical effect
According to China's criterion of therapeutical effect of the Chinese medical disease Standardization of diagnosis and curative effect on lumbar vertebrae hyperosteogeny.Cure:Pain disappears, and closes
Section activity is normal.Take a turn for the better:Pain has mitigated, and joint motion slightly takes a turn for the better.Invalid pain is unchanged, and function of joint is without change.
3.2 treatment results
As shown in table 2：
| Group | Cure | Take a turn for the better | Do not heal | It is efficient |
| Experimental group (50 people) | 48 | 2 | 0 | 100% (50/50) |
Experimental result illustrates that medicine of the present invention can effectively treat osteoproliferation.
Claims (9)
1. a kind of pharmaceutical composition for treating disadvantage disease, it is characterised in that：It is prepared by the bulk drug comprising following weight proportion
Preparation：
20~40 parts of notopterygium root, 10~30 parts of levisticum, 40~60 parts of the root of Chinese clematis, 10~30 parts of Radix Angelicae Sinensis, 30~50 parts of wild aconite root, Xu are long
10~30 parts of minister in ancient times, 60~80 parts of thunder godvine, 20~40 parts of the root of fangji, 40~60 parts of frankincense.
2. pharmaceutical composition according to claim 1, it is characterised in that：It is by the bulk drug comprising following weight proportion
The preparation being prepared from：30 parts of notopterygium root, 20 parts of levisticum, 50 parts of the root of Chinese clematis, 20 parts of Radix Angelicae Sinensis, 40 parts of wild aconite root, 20 parts of paniculate swallowwort, thunder
70 parts of public rattan, 30 parts of the root of fangji, 50 parts of frankincense.
3. pharmaceutical composition according to claim 2, it is characterised in that：It is prepared by the bulk drug of following weight proportion
Preparation：30 parts of notopterygium root, 20 parts of levisticum, 50 parts of the root of Chinese clematis, 20 parts of Radix Angelicae Sinensis, 40 parts of wild aconite root, 20 parts of paniculate swallowwort, thunder godvine
70 parts, 30 parts of the root of fangji, 50 parts of frankincense.
4. the pharmaceutical composition according to claims 1 to 3 any one, it is characterised in that：It is by bulk drug medicinal powder,
The water or extractive with organic solvent of bulk drug are active component, add pharmaceutically conventional auxiliary material or complementary composition and are prepared from
Preparation.
5. the pharmaceutical composition according to claim 4 any one, it is characterised in that：The preparation is oral formulations.
6. pharmaceutical composition according to claim 5, it is characterised in that：The preparation be capsule, decoction, oral liquid,
Granule, powder, pill, tablet.
7. the preparation method of claim 1-6 any one described pharmaceutical composition, it is characterised in that：Step is as follows：
(1) bulk drug is weighed according to proportioning described in claim 1 or 2；
(2) medicinal powder, the water or extractive with organic solvent of bulk drug of material medicine are prepared, pharmaceutically conventional auxiliary material or complementary is added
Composition, obtains final product.
8. claim 1-6 any one described pharmaceutical composition prepare treatment rheumatism medicine in purposes.
9. purposes according to claim 8, it is characterised in that：The medicine is treatment rheumatoid arthritis, rheumatic
The medicine of arthritis, flesh rheumatism and/or osteoproliferation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710108922.8A CN106822271A (en) | 2017-02-27 | 2017-02-27 | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710108922.8A CN106822271A (en) | 2017-02-27 | 2017-02-27 | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106822271A true CN106822271A (en) | 2017-06-13 |
Family
ID=59134052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710108922.8A Pending CN106822271A (en) | 2017-02-27 | 2017-02-27 | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106822271A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184947A (en) * | 2017-07-25 | 2017-09-22 | 成都中医药大学附属医院 | It is a kind of to treat pharmaceutical composition of arthrosis disease and its production and use |
-
2017
- 2017-02-27 CN CN201710108922.8A patent/CN106822271A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 曹国文: "验方治疗慢性风湿关节痛", 《上海中医药杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184947A (en) * | 2017-07-25 | 2017-09-22 | 成都中医药大学附属医院 | It is a kind of to treat pharmaceutical composition of arthrosis disease and its production and use |
| CN107184947B (en) * | 2017-07-25 | 2020-05-01 | 成都中医药大学附属医院 | Pharmaceutical composition for treating osteoarticular diseases and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585316A (en) | Stasis-removing and pain-relieving powder for treating pain and preparation method of powder | |
| CN106511510A (en) | Medicine composition used for treating wind-cold-damp arthralgia and muscle and bone strain | |
| CN105381132A (en) | Drug for treating thyroid nodule | |
| CN106822271A (en) | It is a kind of to treat pharmaceutical composition of rheumatic Bi syndrome and its production and use | |
| CN104162088A (en) | Traditional Chinese medicine composition for relieving rigidity of muscles, activating collaterals and eliminating dampness and preparation method thereof | |
| CN103830672A (en) | Traditional Chinese medicine for treating scapulohumeral periarthritis | |
| CN103599321B (en) | Traditional Chinese medicine composition for treating osteoporosis | |
| CN102406870A (en) | Medicament for treating rheumatic arthralgia | |
| CN105412206A (en) | Traditional Chinese medicine preparation with relaxing tendon and dissipating hard mass effects | |
| CN101361868B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| CN104758835B (en) | A kind of Chinese medicine being used for the treatment of cerebral infarction disease | |
| CN104606313A (en) | Traditional Chinese medicinal ointment for treating osteoarticular diseases and bone fractures | |
| CN101983712A (en) | Novel medicament for treating coronary heart disease | |
| CN103356951B (en) | A kind of Chinese medicine composition for the treatment of cardiac blood supply deficiency | |
| CN102764325B (en) | Chinese medicinal composition for dispelling rheumatism and relieving pain | |
| CN100353995C (en) | Pharmaceutical composition with functions of dispersing pathogenic wind, activating collaterals ,and clearing away toxin | |
| CN103285108B (en) | Chinese medicinal composition treating lumbago | |
| CN102335304B (en) | Chinese medicine composition for dispelling wind, removing dampness, invigorating blood circulation, and relieving pain and preparation method thereof | |
| CN102178758A (en) | Medicament for treating peripheral nerve of diabetes | |
| CN101361882B (en) | Chinese medicine formulation for treating rheumatic osteoarthropathy | |
| CN107913399A (en) | A kind of Chinese and Western for treating osteoporosis combines pharmaceutical composition and preparation method | |
| CN105727118A (en) | Medicinal liquor for treating wind-cold-dampness arthralgia and preparation method for medicinal liquor | |
| CN105381098A (en) | Traditional Chinese medicine fumigating and washing agent for treating knee osteoarthritis and nursing method | |
| CN103251851B (en) | Internal and external traditional Chinese medicine formulation for treating rheumatic and rheumatoid diseases | |
| CN104857350A (en) | Traditional Chinese medicine external lotion for curing acute gouty arthritis and nursing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Liu Kun Inventor after: Li Shimin Inventor after: Ou Wenhui Inventor after: Liu Jun Inventor before: Liu Kun Inventor before: Li Shimin Inventor before: Ou Wenhui Inventor before: Liu Jun Inventor before: Xing Shoukai |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170911 Address after: 413113 Hunan city of Yiyang province Yuanjiang city Yang Luo Zhou Zhen Village eight groups of villagers. Applicant after: Liu Kun Applicant after: Li Shimin Applicant after: Ou Wenhui Applicant after: Liu Jun Address before: 413113 Hunan city of Yiyang province Yuanjiang city Yang Luo Zhou Zhen Village eight groups of villagers. Applicant before: Liu Kun Applicant before: Li Shimin Applicant before: Ou Wenhui Applicant before: Liu Jun Applicant before: Xing Shoukai |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170613 |